Matches in Wikidata for { <http://www.wikidata.org/entity/Q91177773> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q91177773 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91177773 description "scientific article published on 28 August 2018" @default.
- Q91177773 description "wetenschappelijk artikel" @default.
- Q91177773 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91177773 name "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 name "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 type Item @default.
- Q91177773 label "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 label "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 prefLabel "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 prefLabel "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 P1433 Q91177773-2EA1BC3B-E66B-480D-A93A-FC101B0191D4 @default.
- Q91177773 P1476 Q91177773-22D69665-F5F1-44EF-90B2-D9EFAB8CECC9 @default.
- Q91177773 P2093 Q91177773-0AEE03FC-6D4E-4E06-98F8-4F37A01B6616 @default.
- Q91177773 P2093 Q91177773-18F48B6E-D092-4145-BD05-AEB359FDEE87 @default.
- Q91177773 P2093 Q91177773-327FE277-E4C1-4E3C-84FF-3540774BEB34 @default.
- Q91177773 P2093 Q91177773-360C00DD-08F2-4DDA-9E1A-5AD7FDCB7863 @default.
- Q91177773 P2093 Q91177773-37FA1269-307E-4E14-9356-B8020BE8F676 @default.
- Q91177773 P2093 Q91177773-7C4EE6D6-899D-46E2-A6DA-8A505DFBE392 @default.
- Q91177773 P2093 Q91177773-847D06F0-764A-4FDA-B84E-A44534DAFD05 @default.
- Q91177773 P2093 Q91177773-8C0BD6F5-6833-443B-80AE-DF1174A7717E @default.
- Q91177773 P2093 Q91177773-986A52D5-9F5D-4F82-9E03-4FF5FBD806A5 @default.
- Q91177773 P2093 Q91177773-B52F3ED7-314E-4462-B0B7-9260313B4859 @default.
- Q91177773 P2093 Q91177773-B66B5C84-8913-49B6-8E0D-86A296FD5C3C @default.
- Q91177773 P2093 Q91177773-B990D75C-1214-4322-A8A2-7BD06E9EAEAF @default.
- Q91177773 P2093 Q91177773-BD121370-4B81-4685-A8F4-416F7667E40C @default.
- Q91177773 P2093 Q91177773-CA043263-3C85-4899-9A5C-9499C9E1FC0E @default.
- Q91177773 P2093 Q91177773-DA274400-6729-4E16-89FF-6E692B6B8FB8 @default.
- Q91177773 P2093 Q91177773-E451BBEE-912E-47B3-A01D-7B55FBD8A6F3 @default.
- Q91177773 P2093 Q91177773-E4D3B9B9-4D39-4612-8780-8A6E5F86B251 @default.
- Q91177773 P2093 Q91177773-EA706919-112E-4AB1-981C-FD435BE3CC77 @default.
- Q91177773 P304 Q91177773-7DAE2487-6D67-409E-9278-FED6910A8E4E @default.
- Q91177773 P31 Q91177773-6DA75016-E5C2-438B-80FB-939C3AC70C44 @default.
- Q91177773 P356 Q91177773-1FA9DBDC-9467-4850-996F-8F62C43E00A0 @default.
- Q91177773 P50 Q91177773-A8030C6C-1DA0-40C2-A15F-DD9621B8B426 @default.
- Q91177773 P577 Q91177773-AACED9F2-B485-4C14-BC35-0B7A7065CACB @default.
- Q91177773 P698 Q91177773-27CC81D7-B0B9-4F2B-8E34-9E2CFD632732 @default.
- Q91177773 P921 Q91177773-079E2301-5AED-4E10-8BCD-9A4F452C7277 @default.
- Q91177773 P921 Q91177773-1F980415-65C6-4CFC-8139-A8650E0917AD @default.
- Q91177773 P932 Q91177773-4FEC3F01-70B8-48EA-A04C-D498F1517AB2 @default.
- Q91177773 P356 JCO.2018.78.8414 @default.
- Q91177773 P698 30153096 @default.
- Q91177773 P1433 Q400292 @default.
- Q91177773 P1476 "Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features" @default.
- Q91177773 P2093 "Anna L Godfrey" @default.
- Q91177773 P2093 "Bridget S Wilkins" @default.
- Q91177773 P2093 "Cathy MacLean" @default.
- Q91177773 P2093 "Cecily Forsyth" @default.
- Q91177773 P2093 "Claire N Harrison" @default.
- Q91177773 P2093 "French Intergroup of Myeloproliferative Neoplasms" @default.
- Q91177773 P2093 "Georgina Buck" @default.
- Q91177773 P2093 "Jacob Grinfeld" @default.
- Q91177773 P2093 "Jean-Jacques Kiladjian" @default.
- Q91177773 P2093 "Julia Cook" @default.
- Q91177773 P2093 "Julie Temple" @default.
- Q91177773 P2093 "Jyoti Nangalia" @default.
- Q91177773 P2093 "Keith Wheatley" @default.
- Q91177773 P2093 "Mary Frances McMullin" @default.
- Q91177773 P2093 "Peter J Campbell" @default.
- Q91177773 P2093 "United Kingdom Medical Research Council Primary Thrombocythemia-1 Study" @default.
- Q91177773 P2093 "United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup" @default.
- Q91177773 P2093 "and the Australasian Leukaemia and Lymphoma Group." @default.
- Q91177773 P304 "JCO2018788414" @default.
- Q91177773 P31 Q13442814 @default.
- Q91177773 P356 "10.1200/JCO.2018.78.8414" @default.
- Q91177773 P50 Q59963218 @default.
- Q91177773 P577 "2018-08-28T00:00:00Z" @default.
- Q91177773 P698 "30153096" @default.
- Q91177773 P921 Q18216 @default.
- Q91177773 P921 Q212272 @default.
- Q91177773 P932 "6269131" @default.